Method for preparing pluripotent cardiovascular precursor cells and maintaining their cardiovascular differentiation ability
A precursor cell, pluripotent stem cell technology, applied in non-embryonic pluripotent stem cells, artificially induced pluripotent cells, animal cells, etc., can solve problems such as regulation and little understanding of molecular basis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0085] The present invention also includes the cell group containing cardiovascular precursor cells obtained by the aforementioned preparation method. In the cell group, the number of cardiovascular precursor cells accounts for more than 70% of the total number of cells, preferably more than 80% of the total number of cells; more preferably more than 85% of the total number of cells (expressed as surface markers SSEA1 or MESP1 positive cells count).
[0086] Once a cell population containing cardiovascular precursor cells has been obtained, the identification of cardiovascular precursor cells can be achieved using RT-PCR and other gene expression analysis techniques.
[0087] Cardiovascular precursor cells can be identified or isolated or enriched using methods known to those skilled in the art. More classical methods such as fluorescence-activated cell sorting (FACS) or magnetic cell sorting, that is, the use of antibodies against specific surface molecules of cardiovascular...
Embodiment 1
[0193] Example 1. Efficient transformation of human pluripotent stem cells (hPSCs) into homogeneous CVPCs
[0194] To induce hPSCs towards a cardiovascular fate, the inventors screened important signal transduction pathways during mesoderm formation and subsequent cardiac differentiation, including Wnt, GSK3, FGF, BMP and Activin / Nodal. In order to make the conditions uniform, the inventors used a single cell-based differentiation method on the basis of a monolayer culture system, and added the Rho kinase inhibitor Y27632 in the first day of differentiation to improve the survival of the cells. After a series of systematic attempts, the inventors found that the joint addition of 25ng / ml BMP4, 50μg / ml AA and 3μM GSK3 inhibitor CHIR99021 (CHIR) (the mixture of these combined reagents is named CIM) can effectively remove the The undifferentiated human embryonic stem cell line H9 was converted into a homogeneous cell population, most of which (88.9 ± 1.8%) expressed the recently i...
Embodiment 2
[0197] Example 2. Long-term maintenance of self-renewal of hPSC-derived CVPCs
[0198] Proliferation and lineage determination of CVPCs are regulated by a delicate microenvironment and complex levels of multiple signal transduction pathways, including Wnt, FGF, BMP, Notch, Hedgehog, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF ), MEK, retinoic acid (RA), and Activin / Nodal. Therefore, under specific conditions in vitro, it is generally difficult to maintain the self-renewal and expansion of CVPCs. The inventors hypothesized that if the conditions that induce CVPC differentiation are concertedly eliminated, they should be able to maintain basal state self-renewal and continued proliferation. To verify it, the inventors selected 9 signaling pathway inhibitors together with the GSK3 inhibitor CHIR (CHIR99021) (Table 3) to verify their role in stimulating CVPC expansion. Clonogenicity was not observed in H9-derived CVPCs on day 3 of differentiat...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com